Nyrada Inc : Cholesterol-Lowering Program Update
Nyrada Inc (ASX: NYR), a drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases,… Read more
Nyrada Inc (ASX: NYR), a drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases,… Read more
New brain injury drug candidate NYR-BI03 to be advanced instead of NYR-BI02 due to demonstrated superior potency and safety profile,… Read more
• All required preclinical safety and toxicology studies have been completed, supporting advancement to a first-in-human clinical trial • Submission… Read more
Highlights: • Cholesterol-Lowering Program: – Preclinical dose formulation work finalised – Remaining safety and pharmacology studies to be completed end… Read more
• Preclinical dose formulation work has been completed • Toxicology studies have been completed, safety and pharmacology studies to be… Read more
• Collaboration with the Walter Reed Army Institute of Research (WRAIR) and UNSW Sydney (UNSW) extended from February 2023 through… Read more
• In vitro safety and toxicology studies commenced 2H CY2022 and are tracking well • No change to start of… Read more
Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and… Read more
Sydney, 27 October 2022: Nyrada Inc (ASX: NYR) (“Nyrada” or “the Company”) a preclinical stage, drug development company specialising in… Read more